As a result, vitamin C may help reduce the risk of anemia among people prone to iron deficiency
I am scrolling between sessions at a CE conference, and the last speaker actually discussed this study!
To assess the associations of semaglutide with incident CUD (first time diagnosis of CUD), the study population included 83,189 patients who had active medical encounters for the diagnosis of obesity in 6/202112/2022, were for the first time (new users design) prescribed semaglutide or non-GLP-1RA anti-obesity medications (bupropion, naltrexone, orlistat, topiramate, phentermine) [39] during 6/2021-12/2022 (time zero or index event), had no diagnosis of CUD on or before the index event and had a diagnosis of at least one of obesity-associated comorbidities (T2D, hypertension, hypercholesterolemia, hyperlipidemia, heart diseases, stroke) on or before the index event
The Precision Peptide Genetic Test reveals predispositions in GLP-1 and GIP receptor pathways, but it does not predict your exact medication response or guarantee specific side effect timelines
Extended Clinic License Upgrade (MultiLocation / MultiDomain)